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Endoplasmic reticulum (ER) stress is a physiological response to protein overload or misfolded proteins
in the ER. Certain anti-cancer drugs, e.g. bortezomib and nelﬁnavir, induce ER stress implying that this
could be a successful therapeutic strategy against several forms of cancer. To ﬁnd novel ER-stress in-
ducers we screened a panel of natural and synthetic Toll-like receptor (TLR) agonists against human
keratinocytes and identiﬁed the anti-cancer drug imiquimod (IMQ) as a potent inducer of ER stress.
Other TLR7 and TLR8 agonists, including resiquimod and gardiquimod, did not induce ER stress,
demonstrating that IMQ induces ER stress independently of TLR7 and TLR8. We further conﬁrmed this by
showing that IMQ could still induce ER stress in mouse Tlr7/ cells. IMQ also induced a rapid and
transient inﬂux of extracellular Ca2þ together with the release of Ca2þ from internal stores. Depletion of
Ca2þ from the ER is a known cause of ER stress suggesting that IMQ induces ER stress via depletion of ER
Ca2þ. The ER-stress inducing property of IMQ is possibly of importance for its efﬁcacy in treating basal
cell carcinoma, in situ melanoma, and squamous cell carcinoma. Our data could potentially be harnessed
for rational design of even more potent ER-stress inducers and new anti-cancer drugs.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Endoplasmic reticulum (ER) stress is a physiological response
that occurs after protein overload, or accumulation of misfolded
proteins, in the ER lumen. ER stress triggers the highly conserved
unfolded-protein response (UPR) mediated by IRE1-dependent
splicing of XBP1 mRNA, proteolytic processing of ATF6 and the
phosphorylation of PERK [1,2]. This in turn is followed by the in-
duction of ER-stress target genes including pro- or anti-apoptotic
genes, chaperone genes and phospholipid-synthesis genes, e.g.
DDIT3 (CHOP), ERDJ4, GRP78 (BiP), and EPT1 [3]. Chronic and high
levels of ER stress induce cell death whereas moderate or transient
ER stress serves a protective role for stressed cells, e.g. during tumor
growth [4]. Tipping the balance of ER stress towards cell death has
recently emerged as a successful anti-cancer strategy. The anti-
cancer drugs bortezomib, nelﬁnavir and tanespimycin all act via
the induction of ER stress followed by apoptosis or reduced growtheumatology, Department of
, Karolinska Institutet, SE-171
osa).
Inc. This is an open access article uof cancer cells [5e8]. Since pharmacologically induced ER stress
seems effective against certain forms of cancer, a search for addi-
tional potent ER-stress inducers is motivated.
Toll-like receptor (TLR) signaling can trigger the activation of
XBP1, PERK and ATF6 in macrophages, but with little or no induc-
tion of classical ER-stress target genes [9]. In addition, TLR signaling
also leads to splicing of XBP1 followed by induction of pro-
inﬂammatory genes in synoviocytes and by apoptosis in intestinal
stem cells [10,11]. Since skin responds with ER stress after exposure
to several environmental factors, we hypothesized that keratino-
cytes, in contrast tomacrophages, would be prone to a full ER-stress
response after exposure to natural or synthetic TLR agonists
[12e14]. Indeed, while screening TLR agonists against primary
human keratinocytes we identiﬁed the synthetic TLR7-agonist
imiquimod (IMQ) as a potent inducer of ER stress. IMQ is a purine
analog with anti-cancer properties and is the prototypic compound
of the imidazoquinolines, a group of small immunostimulatory
molecules including resiquimod (RSQ) and gardiquimod (GDQ)
[15]. IMQ triggers TLR7 signaling followed by the expression of pro-
inﬂammatory factors such as IFNa, IL6 and TNF [16]. However, it is
well established that IMQ also provokes TLR7-independent re-
sponses in skin. Topical IMQ cream (Aldara) induces strong re-
sponses in skin of Tlr7/ and Myd88/ mice independently ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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IMQ induces ER stress in a TLR7-independent manner in kerati-
nocytes and melanoma cells. Interestingly, other TLR7 and TLR8
agonists, including RSQ and GDQ, were unable to induce ER stress
indicating that small structural changes in imidazoquinolines im-
pacts their ER-stress inducing activity.
While trying to understand the mechanism whereby IMQ in-
duces ER stress we discovered that IMQ induced a rapid and tran-
sient inﬂux of extracellular Ca2þ and a release of intracellular Ca2þ
stores. Depletion of Ca2þ from the ER lumen is a known cause of ER
stress, mediated by the interference with Ca2þ-dependent chaper-
ones. This suggests that IMQ induces ER stress via depletion of Ca2þ
from the ER [19]. Identifying the receptor for IMQ that mediates the
induction of ER stress could potentially lead to the discovery of
endogenous ligands that control physiological ER-stress responses.
Furthermore, the data provided here might be useful for rational
design of strong ER-stress inducers and new anti-cancer drugs.
2. Material and methods
2.1. Cells
Neonatal human keratinocytes (Life Technologies) were
cultured in keratinocyte-SFM medium (Gibco) supplemented with
0.2 ng/ml recombinant epidermal growth factor (EGF) and 30 mg/ml
of bovine pituitary extract (BPE) (Gibco). The medium was addi-
tionally supplemented with 0.3 mM CaCl2, penicillin (100 U/ml)Fig. 1. IMQ induces a TLR7-independent ER-stress response. Using primary human kerati
used XBP1 splicing as a marker for ER stress and identiﬁed IMQ as a potent inducer of ER s
cells do not express TLR7 or TLR8, clearly indicating that the IMQ-induced ER-stress respons
response occurs independently of TLR7 we stimulated mouse Tlr7/ and WT splenocytes w
measured by induction of the ER-stress gene CHOP (Ddit3). The potent TLR7-agonist GDQ co
Dunnett's post-test, *** ¼ p < 0.01.)and streptomycin (100 mg/ml) (Gibco). Human melanoma cell lines
A375, SK-MEL-28 and MeWo (ATCC) were cultured in DMEM me-
dium supplemented with 5% fetal calf serum, penicillin (100 U/ml),
streptomycin (100 mg/ml) and glutamine (1 mM). Mouse spleno-
cytes were isolated fromWT and Tlr7/mice and were cultured in
RPMI-1640 medium supplemented with 10% fetal calf serum,
penicillin (100 U/ml), streptomycin (100 mg/ml), glutamine (1 mM)
and b-mercaptoethanol (50 mM).
2.2. Quantitative RT-PCR
Total RNA was isolated using TRIzol (Life Technologies) using
chloroform and isopropanol precipitation. After one wash in 70%
ethanol the concentration of total RNA was determined using
NanoDrop 1000 (Thermo Scientiﬁc). Total RNA was reverse tran-
scribed in cDNA using the High-Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems) or iScript cDNA synthesis kit (Bio-
Rad). Gene expression levels were determined by real-time PCR
using SYBR reagent on an Mx3005P (Agilent Technologies) or
TaqMan probes (Thermo Scientiﬁc) on a LightCycler 96 (Roche).
Primer sequences and more information on SYBR and TaqMan as-
says are available on request.
2.3. Calcium measurements
A375 were loaded with Fluo-3 AM (1 mM) (Thermo Scientiﬁc) in
PBS (0.9% Ca2þ) buffer containing pluronic acid (0.02%) andnocytes we screened a panel of TLR agonists to identify novel inducers of ER stress. We
tress in human keratinocytes (A). Primary human keratinocytes and human melanoma
e is independent of TLR7 and TLR8 (B). To further verify that the IMQ-induced ER-stress
ith IMQ (C). Indeed, IMQ induced an ER-stress response both in Tlr7/ and WT cells as













































Fig. 2. Structureeactivity relationship among imidazoquinolines. IMQ belongs to
the imidazoquinolines, a group of small purine analogs that are commonly used as
TLR7 or TLR8 agonists (A). After treating A375 melanoma cells with different imida-
zoquinolines we analyzed their ability to induce XBP1 splicing (B and C). Only IMQ and
3M-011 were able to induce XBP1 splicing indicating that small structural variations
among imidazoquinolines affect their ability to induce ER stress.
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25 C (protected from light) the cells were washed twice in PBS
(with 1 mM probenecid) and incubated for another 30 min at 25 C
(protected from light). After a last wash in PBS the cells were ac-
quired. To trigger Ca2þ ﬂux cells were treated with imiquimod,
CL075, resiquimod (all from Invivogen) at 25 ug/ml. Ionomycin
(1 mM) was used as a positive control (Sigma Aldrich). To block
extracellular Ca2þ we added EGTA (1 mM) before acquisition
(Sigma Aldrich). To inhibit CRAC channels we added the CRAC in-
hibitor BPT2 (10 mM) before acquisition (Calbiochem). All cells were
acquired using an LSRII cytometer (Becton Dickinson) using the
FACSDiva (Becton Dickinson). Data was analyzed using FlowJo
(FlowJo, LLC).
2.4. XBP1 splicing assay
After RNA isolation and reverse-transcription into cDNA,
endpoint PCR was performed using the following primers: XBP1-F:
CCTGGTTGCTGAAGAGGAGG, and XBP1-R: CCATGGGGA-
GATGTTCTGGAG. The PCR programwas initiated by a denaturation
step at 94 C for 3 min, followed by 30 cycles of: 30 s 94 C, 30 s
58 C, 30 s 72 C. The programwas endedwith a 3min step at 72 C.
The PCR products were separated on a 2.5% agarose gel. Unspliced
XBP1 appeared as a 145 bp band, while spliced XBP1 appeared as a
119 bp band.
2.5. Flow cytometry
A375 cells were incubated with IMQ (25 mg/ml) or RSQ (25 mg/
ml) in PBS for 15 min at 25 C followed by two washes with PBS.
IMQ was excited with an ultraviolet laser (355 nm) and the ﬂuo-
rescence was detected using the 440/40 ﬁlter set. All cells were
acquired using an LSRII cytometer (Becton Dickinson) using the
FACSDiva (Becton Dickinson). Data was analyzed using FlowJo
(FlowJo, LLC).
3. Results
3.1. IMQ induces a strong ER-stress response in primary human
keratinocytes independently of TLR7 and TLR8
We screened a panel of natural and synthetic TLR and NOD
agonists (TLR2, TLR3, TLR4, TLR5, TLR7 and NOD2) to identify those
capable of inducing ER stress in primary human keratinocytes. We
used the known ER-stress inducer tunicamycin (TM) as a positive
control for XBP1 splicing. After incubation for 6 h we identiﬁed ER-
stress inducing TLR agonists through an XBP1-splicing assay
(Fig. 1A). The only TLR agonist that could induce XBP1 splicing in
keratinocytes was IMQ, detected by the appearance of spliced
XBP1 (XBP1s) at 119 bp after RT-PCR. The induction of XBP1
splicing by IMQ was concentration dependent and at concentra-
tions 25 mg/ml the splicing of XBP1 was near complete in kera-
tinocytes (Supplementary Fig. 1A). IMQ is a well-known TLR7
agonist, however, we did not detect neither TLR7 nor TLR8
expression in human keratinocytes and melanoma cells demon-
strating that the ER-stress inducing properties of IMQ are inde-
pendent of TLR7 and TLR8 (Fig. 1B, Supplementary Fig. 1B). Indeed,
several reports have previously determined that human kerati-
nocytes do not express TLR7 and TLR8 [20,21]. We further veriﬁed
that IMQ acts in a TLR7-independent manner by successfully
inducing ER stress both in Tlr7/ and WT mouse splenocytes with
IMQ (Fig. 1C). The potent TLR7-agonist GDQ could not induce ER
stress neither in Tlr7/ nor WT cells, conﬁrming that IMQ induces
ER stress independently of TLR7. In addition, the TRPV1-agonist
capsaicin (CAPS) did not induce ER stress demonstrating thatIMQ does not act via the receptor TRPV1 as previously suggested
[18]. To verify that the IMQ-induced splicing of XBP1 occurred via
IRE1 we used S2Rþ cells for efﬁcient knockdown of IRE1 followed
by stimulation with IMQ for 6 h. In the absence of IRE1, IMQ was
unable to induce splicing of XBP1 whereas the control knockdown
of GFP did not affect the splicing of XBP1 (Supplementary Fig. 1C).
To conﬁrm that IMQ triggers a bona ﬁde ER-stress response we
veriﬁed that IMQ induced the expression of ER-stress genes
including ERDJ4, DDIT3 (CHOP) and GRP78 (BiP) (Supplementary
Fig. 1D).3.2. Structureeactivity relationship among imidazoquinolines
IMQ is the original member of the antiviral imidazoquinolines, a
group of purine analogs that are potent TLR7 or TLR8 agonists.
Originally developed as antiviral compounds the imidazoquino-
lines also include RSQ, CL075, GDQ and 3M-011 (Fig. 2A). IMQ
induced XBP1 splicing in human melanoma cells (Fig. 2B); in
contrast, RSQ, CL075 and GDQ were unable to induce ER stress
(Figs. 2B and 1C). Treatment with IMQ led to apoptosis of mela-
noma cells and also potently induced cell-growth arrest
(Supplementary Fig. 2A, B). In contrast, RSQ did not induce cell-
growth arrest in melanoma cells (Supplementary Fig. 2B). This in-
dicates that the ER-stress inducing and pro-apoptotic activity of
IMQ is different from its structurally similar analogs RSQ, GDQ and
CL075. Interestingly, the imidazoquinoline 3M-011 could induce
XBP1 splicing in melanoma cells suggesting that IMQ and 3M-011
share structural similarities that enable them to induce ER stress in
a TLR7-independent manner (Fig. 2C). This structureeactivity
relationship could be used for developing more potent ER-stress
inducing imidazoquinolines with stronger anti-cancer properties.
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independently of TLR7 and IP3R
Since IMQ is a purine analog we hypothesized that it induces
inﬂux of extracellular Ca2þ in a manner similar to ATP. Indeed,
addition of IMQ to melanoma cells induced a fast and transient rise
in cytosolic [Ca2þ] asmeasured by Fluo-3-AM (Fig. 3A). Interestingly,
neither RSQ nor CL075 induced inﬂux of Ca2þ, demonstrating that
the Ca2þ-inducing property of IMQ is independent of TLR7. To
identify Ca2þ-associated pathways triggered by IMQ we pre-
incubated melanoma cells with a panel of inhibitors followed by
addition of IMQ. None of the tested inhibitors could block XBP1
splicing (Supplementary Fig. 3A) or Ca2þ inﬂux (data not shown)
indicating that IMQ acts independently of extracellular Ca2þ, P2X7
channels, phospholipase C (PLC), phosphoinositol 3-kinase (PI3K)
and protein kinase C (PKC). At high concentrations the IP3R inhibitor
2-APB (100 mM) inhibited XBP1 splicing and Ca2þ inﬂux (data not
shown). However, at such high concentrations 2-APB and suffer
from severe non-speciﬁc effects [22]. Importantly, blocking extra-
cellular Ca2þ with 1 mM EGTA did not inhibit XBP1 splicing but
revealed that IMQ induced the release of Ca2þ from intracellular
stores (Fig. 3B). To verify that IMQ induced splicing of XBP1 was
independent of store-operated calcium entry we inhibited calciumFig. 3. IMQ induces the release of Ca2þ from intracellular stores independently of TLR7
melanoma cells, while RSQ and CL075 did not affect cytosolic Ca2þ levels. Ionomycin was
observed a release of Ca2þ from intracellular stores after treatment with IMQ (B). To test if IM
with BTP-2 followed by cytosolic Ca2þ measurements (C) and XBP1-splicing assays (D). In a
Ca2þ.release-activated channels (CRAC) by pre-treatment of melanoma
cells with the CRAC inhibitor BTP-2 (10 mM). Indeed, BPT-2 blocked
the inﬂux of extracellular Ca2þ without affecting the release of
intracellular Ca2þ stores (Fig. 3C). Also, blocking CRAC channels with
BTP-2 did not block the induction of XBP1 splicing by IMQ (Fig. 3D).
This again veriﬁed that the ER stress inducing activity of IMQ is
independent of extracellular Ca2þ. The release of intracellular Ca2þ
suggests that IMQ leads to opening of IP3R in the ER membrane.
Surprisingly, DT40 cells lacking all isoforms of IP3R still responded
to IMQ by XBP1 splicing and Ca2þ inﬂux (Supplementary Fig. 3B, C)
[23]. This indicates that IMQ, in contrast to previous reports, triggers
Ca2þ inﬂux and ER stress independently of both TLR7 and IP3R
[24,25]. Since IMQ is a purine analog and capable of inducing ER
stress and inﬂux of Ca2þ we hypothesized that it acts via purinergic
P2Y or P2X receptors. To test this we treated A375 melanoma cells
with different P2X and P2Y agonists (Supplementary Fig. 3D, E). In
addition we pre-treated cells with the P2X antagonist suramin to
determine if it could inhibit the activity of IMQ (Supplementary
Fig. 3E). Natural and synthetic P2X and P2Y agonists were unable
to induce XBP1 splicing, and blocking P2X receptors using suramin
did not affect the activity of IMQ. This suggests that IMQ might
induce XBP1 splicing independently of purinergic receptors. It has
been reported that IMQ can signal via adenosine receptors [26].and IP3R. IMQ induced a strong, rapid, and transient increase in cytosolic Ca2þ in A375
used as a positive control (A). After blocking extracellular Ca2þ with 1 mM EGTA we
Q induces XBP1-splicing independently of extracellular Ca2þwe blocked CRAC channels
ll, IMQ was still able to induce XBP1 splicing when blocking the entry of extracellular
Fig. 4. IMQ binds to proteinase-K sensitive receptors on the surface of melanoma cells. We used the ﬂuorescent properties of IMQ and RSQ to stain A375 melanoma cells
followed by ﬂow cytometry using excitationwith an ultraviolet laser (355 nm) and detection using the 440/40 ﬁlter set. Binding of IMQ to A375 melanoma cells was readily detected
after ﬂow cytometry (A). In contrast, RSQ was unable to stain the cells. Pre-treatment of melanoma cells with proteinase K reduced the binding of IMQ indicating that IMQ induces
ER-stress by binding to at least one protein-based cell-surface receptor (B).
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cells (Supplementary Fig. 3F, G). In all, IMQ induces the inﬂuxof Ca2þ
via an unknown mechanism and we suggest that IMQ induces ER
stress via depletion of Ca2þ from the ER.
3.4. IMQ binds to a proteinase-K sensitive receptor on the surface of
melanoma cells
Since the ﬂuorescent properties of IMQ and RSQ previously have
been used to measure release of IMQ from topical formulations and
the encapsulation efﬁciency of RSQ we asked if these properties
could be exploited for staining A375 melanoma cells with IMQ and
RSQ. For IMQ it has experimentally been determined that the
excitationmax ¼ 235 nm and emissionmax ¼ 341 nm [27].
Excitation ¼ 260 nm and emission ¼ 360 nm has successfully been
used for ﬂuorescent detection of RSQ [28]. Addition of IMQ to A375
melanoma cells stained the cells as detected by ﬂowcytometry using
an ultraviolet laser (355 nm) and the Paciﬁc Blue (440/40) ﬁlter
setting (Fig. 4A). In contrast, RSQ were unable to stain A375 mela-
noma cells using the same approach. This strongly suggests that a
non-TLR7 receptor for IMQ is expressed on A375melanoma cells and
that this receptor is not bound by RSQ. To verify that the effect of
IMQ is mediated via a cell surface receptor, we pre-treated the
melanoma cells with proteinase K followed bywashing and addition
of IMQ. Indeed, proteinase-K treatment clearly inhibited the binding
of IMQ (Fig. 4B). In all, our data suggests that IMQ binds a non-
purinergic receptor that triggers the inﬂux of Ca2þ and ER stress.
4. Discussion
IMQ has been successfully used as an immunostimulatory
molecule for almost 30 years. Even though the identiﬁcation of TLR7
as the receptor for IMQ clariﬁed many of its immunostimulatoryproperties, it is evident that imiquimod also have TLR7- andMyD88-
independent effects. Many cell types lacking TLR7 and TLR8 still
respond to IMQ, and topical treatment of Tlr7/ andMyd88/mice
with IMQ nevertheless induces strong reactions in skin [17,18]. Thus
the role of IMQ as a potent inducer of ER stress and apoptosis might
explain some of the TLR7-independent effects of IMQ. In stark
contrast to its close analogs RSQ, CL075 and GDQ, treatment with
IMQ leads to XBP1 splicing and the induction of ER-stress target
genes. This is a surprising ﬁnding given the close structural simi-
larities between IMQ, RSQ, CL075 and GDQ, and could potentially be
used for structureeactivity relationship studies to obtain new more
potent ER-stress inducers. In addition to IMQ, we also identiﬁed the
imidazoquinoline 3M-011 as an inducer of XBP1 splicing suggesting
that new imidazoquinoline variants with greater ER-stress inducing
activity could be generated. To our knowledge IMQ is the third FDA
approved drug that induces ER stress, the others being the anti-
cancer drug bortezomib and the anti-HIV drug nelﬁnavir. Since
nelﬁnavir, bortezomib and IMQ are effective against certain forms of
cancer, it appears that ER-stress inducers in general could be
effective anti-cancer drugs. This motivates a search for additional
ER-stress inducers. While the proteasome inhibitor bortezomib
triggers ER-stress via the induction of protein misfolding in the ER,
we demonstrate that IMQ appears to induce ER stress via depletion
of Ca2þ from the ER. IMQ induces a rapid depletion of Ca2þ from the
ER and inﬂux of extracellular Ca2þ. Identifying the unknown IMQ
receptor could potentially lead to the discovery of new physiological
pathways for induction of ER stress, and to development of new
more potent pharmacological inducers of ER stress.Acknowledgments
This work was funded by the Swedish Research Council (VR)
(K2013-99X-22235-01-5); the Center of excellence for research on
W.A. Nyberg, A. Espinosa / Biochemical and Biophysical Research Communications 473 (2016) 789e794794inﬂammation and cardiovascular disease (CERIC); and Karolinska
Institutet, Sweden. The authors thank Professor Laurie Glimcher for
valuable scientiﬁc input. The authors declare no conﬂict of interest.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.bbrc.2016.03.080.
Transparency document
Transparency document related to this article can be found
online at http://dx.doi.org/10.1016/j.bbrc.2016.03.080.
References
[1] D. Ron, P. Walter, Signal integration in the endoplasmic reticulum unfolded
protein response, Nat. Rev. Mol. Cell Biol. 8 (2007) 519e529.
[2] H. Yoshida, T. Matsui, A. Yamamoto, T. Okada, K. Mori, XBP1 mRNA is induced
by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active
transcription factor, Cell 107 (2001) 881e891.
[3] A.H. Lee, N.N. Iwakoshi, L.H. Glimcher, XBP-1 regulates a subset of endo-
plasmic reticulum resident chaperone genes in the unfolded protein response,
Mol. Cell. Biol. 23 (2003) 7448e7459.
[4] M. Maurel, E.P. McGrath, K. Mnich, S. Healy, E. Chevet, A. Samali, Controlling
the unfolded protein response-mediated life and death decisions in cancer,
Semin. Cancer Biol. 33 (2015) 57e66.
[5] A. Fribley, Q. Zeng, C.Y. Wang, Proteasome inhibitor PS-341 induces apoptosis
through induction of endoplasmic reticulum stress-reactive oxygen species in
head and neck squamous cell carcinoma cells, Mol. Cell. Biol. 24 (2004)
9695e9704.
[6] E.A. Obeng, L.M. Carlson, D.M. Gutman, W.J. Harrington Jr., K.P. Lee, L.H. Boise,
Proteasome inhibitors induce a terminal unfolded protein response in mul-
tiple myeloma cells, Blood 107 (2006) 4907e4916.
[7] J.J. Gills, J. Lopiccolo, J. Tsurutani, R.H. Shoemaker, C.J. Best, M.S. Abu-Asab,
J. Borojerdi, N.A. Warfel, E.R. Gardner, M. Danish, M.C. Hollander, S. Kawabata,
M. Tsokos, W.D. Figg, P.S. Steeg, P.A. Dennis, Nelﬁnavir, A lead HIV protease
inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic
reticulum stress, autophagy, and apoptosis in vitro and in vivo, Clin. Cancer
Res. 13 (2007) 5183e5194.
[8] P. Pyrko, A. Kardosh, W. Wang, W. Xiong, A.H. Schonthal, T.C. Chen, HIV-1
protease inhibitors nelﬁnavir and atazanavir induce malignant glioma death by
triggering endoplasmic reticulum stress, Cancer Res. 67 (2007) 10920e10928.
[9] F. Martinon, X. Chen, A.H. Lee, L.H. Glimcher, TLR activation of the transcrip-
tion factor XBP1 regulates innate immune responses in macrophages, Nat.
Immunol. 11 (2010) 411e418.
[10] S. Savic, L. Ouboussad, L.J. Dickie, J. Geiler, C. Wong, G.M. Doody,
S.M. Churchman, F. Ponchel, P. Emery, G.P. Cook, M.H. Buch, R.M. Tooze,
M.F. McDermott, TLR dependent XBP-1 activation induces an autocrine loop
in rheumatoid arthritis synoviocytes, J. Autoimmun. 50 (2014) 59e66.
[11] A. Afrazi, M.F. Branca, C.P. Sodhi, M. Good, Y. Yamaguchi, C.E. Egan, P. Lu, H. Jia,
S. Shafﬁey, J. Lin, C. Ma, G. Vincent, T. Prindle Jr., S. Weyandt, M.D. Neal,
J.A. Ozolek, J. Wiersch, M. Tschurtschenthaler, C. Shiota, G.K. Gittes, T.R. Billiar,
K. Mollen, A. Kaser, R. Blumberg, D.J. Hackam, Toll-like receptor 4-mediated
endoplasmic reticulum stress in intestinal crypts induces necrotizing
enterocolitis, J. Biol. Chem. 289 (2014) 9584e9599.
[12] S. Toosi, S.J. Orlow, P. Manga, Vitiligo-inducing phenols activate the unfolded
protein response in melanocytes resulting in upregulation of IL6 and IL8,
J. Investig. Dermatol. 132 (2012) 2601e2609.[13] M.R. Farrukh, U.A. Nissar, Q. Afnan, R.A. Raﬁq, L. Sharma, S. Amin, P. Kaiser,
P.R. Sharma, S.A. Tasduq, Oxidative stress mediated Ca(2þ) release manifests
endoplasmic reticulum stress leading to unfolded protein response in UV-B
irradiated human skin cells, J. Dermatol. Sci. 75 (2014) 24e35.
[14] K. Sugiura, Unfolded protein response in keratinocytes: impact on normal and
abnormal keratinization, J. Dermatol. Sci. 69 (2013) 181e186.
[15] J.F. Gerster, K.J. Lindstrom, R.L. Miller, M.A. Tomai, W. Birmachu,
S.N. Bomersine, S.J. Gibson, L.M. Imbertson, J.R. Jacobson, R.T. Knaﬂa,
P.V. Maye, N. Nikolaides, F.Y. Oneyemi, G.J. Parkhurst, S.E. Pecore, M.J. Reiter,
L.S. Scribner, T.L. Testerman, N.J. Thompson, T.L. Wagner, C.E. Weeks,
J.D. Andre, D. Lagain, Y. Bastard, M. Lupu, Synthesis and structure-activity-
relationships of 1H-imidazo[4,5-c]quinolines that induce interferon produc-
tion, J. Med. Chem. 48 (2005) 3481e3491.
[16] H. Hemmi, T. Kaisho, O. Takeuchi, S. Sato, H. Sanjo, K. Hoshino, T. Horiuchi,
H. Tomizawa, K. Takeda, S. Akira, Small anti-viral compounds activate im-
mune cells via the TLR7 MyD88-dependent signaling pathway, Nat. Immunol.
3 (2002) 196e200.
[17] A. Walter, M. Schafer, V. Cecconi, C. Matter, M. Urosevic-Maiwald, B. Belloni,
N. Schonewolf, R. Dummer, W. Bloch, S. Werner, H.D. Beer, A. Knuth, M. van
den Broek, Aldara activates TLR7-independent immune defence, Nat. Com-
mun. 4 (2013) 1560.
[18] S.J. Kim, G.H. Park, D. Kim, J. Lee, H. Min, E. Wall, C.J. Lee, M.I. Simon, S.J. Lee,
S.K. Han, Analysis of cellular and behavioral responses to imiquimod reveals a
unique itch pathway in transient receptor potential vanilloid 1 (TRPV1)-
expressing neurons, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 3371e3376.
[19] A. Celli, D.S. Mackenzie, D.S. Crumrine, C.L. Tu, M. Hupe, D.D. Bikle, P.M. Elias,
T.M. Mauro, Endoplasmic reticulum Ca2þ depletion activates XBP1 and con-
trols terminal differentiation in keratinocytes and epidermis, Br. J. Dermatol.
164 (2011) 16e25.
[20] M.C. Lebre, A.M. van der Aar, L. van Baarsen, T.M. van Capel, J.H. Schuitemaker,
M.L. Kapsenberg, E.C. de Jong, Human keratinocytes express functional toll-
like receptor 3, 4, 5, and 9, J. Investig. Dermatol. 127 (2007) 331e341.
[21] G. Kollisch, B.N. Kalali, V. Voelcker, R. Wallich, H. Behrendt, J. Ring, S. Bauer,
T. Jakob, M. Mempel, M. Ollert, Various members of the Toll-like receptor
family contribute to the innate immune response of human epidermal kera-
tinocytes, Immunology 114 (2005) 531e541.
[22] M.D. Bootman, T.J. Collins, L. Mackenzie, H.L. Roderick, M.J. Berridge,
C.M. Peppiatt, 2-aminoethoxydiphenyl borate (2-APB) is a reliable blocker of
store-operated Ca2þ entry but an inconsistent inhibitor of InsP3-induced
Ca2þ release, FASEB J. 16 (2002) 1145e1150.
[23] H. Sugawara, M. Kurosaki, M. Takata, T. Kurosaki, Genetic evidence for
involvement of type 1, type 2 and type 3 inositol 1,4,5-trisphosphate re-
ceptors in signal transduction through the B-cell antigen receptor, EMBO J. 16
(1997) 3078e3088.
[24] H. Hwang, H. Min, D. Kim, S.W. Yu, S.J. Jung, S.Y. Choi, S.J. Lee, Imiquimod
induces a Toll-like receptor 7-independent increase in intracellular calcium
via IP(3) receptor activation, Biochem. Biophys. Res. Commun. 450 (2014)
875e879.
[25] A. El-Khattouti, D. Selimovic, M. Hannig, E.B. Taylor, Z.Y. Abd Elmageed,
S.Y. Hassan, Y. Haikel, E. Kandil, M. Leverkus, R.T. Brodell, M. Megahed,
M. Hassan, Imiquimod-induced apoptosis of melanoma cells is mediated by
ER stress-dependent Noxa induction and enhanced by NF-kappaB inhibition,
J. Cell. Mol. Med. 20 (2016) 266e286.
[26] M.P. Schon, M. Schon, Imiquimod: mode of action, Br. J. Dermatol. 157
(Suppl. 2) (2007) 8e13.
[27] B. Zhao, Y.Z. Rong, X.H. Huang, J.S. Shen, Experimental and theoretical study
on the structure and electronic spectra of imiquimod and its synthetic in-
termediates, Bioorg. Med. Chem. Lett. 17 (2007) 4942e4946.
[28] A.D. Duong, S. Sharma, K.J. Peine, G. Gupta, A.R. Satoskar, E.M. Bachelder,
B.E. Wyslouzil, K.M. Ainslie, Electrospray encapsulation of toll-like receptor
agonist resiquimod in polymer microparticles for the treatment of visceral
leishmaniasis, Mol. Pharm. 10 (2013) 1045e1055.
